Soligenix shares are trading lower after the company announced clinical results from a comparative study evaluating HyBryte against Valchlor in the treatment of cutaneous T-cell lymphoma. The stock initially traded higher, but it has since reversed.
Portfolio Pulse from Benzinga Newsdesk
Soligenix shares are trading lower after the company announced clinical results from a comparative study evaluating HyBryte against Valchlor in the treatment of cutaneous T-cell lymphoma. The stock initially traded higher, but it has since reversed.
June 25, 2024 | 7:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Soligenix shares are trading lower after the company announced clinical results from a comparative study evaluating HyBryte against Valchlor in the treatment of cutaneous T-cell lymphoma. The stock initially traded higher, but it has since reversed.
The announcement of clinical results is a significant event for biotech companies like Soligenix. The initial positive reaction followed by a reversal suggests that the market may have found the results less favorable upon closer inspection, leading to a decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100